Arginine butyrate increases the cytotoxicity of DAB389IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rβ gene

Leukemia Research

Volumn 26, Issue 12, 2002, Pages 1077-1083

  Shao, Richard H ^a   Tian, Xuejun ^a   Gorgun, Gullu ^a   Urbano, Alexander G ^a   Foss, Francine M ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

Arginine butyrate; Cutaneous T cell lymphoma (CTCL); DAB389IL 2; Histone deacetylase (HDAC) inhibitor; IL 2 receptor (IL 2R); Interleukin 2 (IL 2); ONTAK; Signal transduction pathway; T cell lymphoma leukemia

Indexed keywords

ARGININE BUTYRATE; BUTYRIC ACID DERIVATIVE; DENILEUKIN DIFTITOX; HISTONE DEACETYLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2 RECEPTOR; PROTEIN SUBUNIT; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ARTICLE; CELL GROWTH; CONTROLLED STUDY; CYCLIC AMP RESPONSIVE ELEMENT; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYMPHOMA CELL LINE; PRIORITY JOURNAL; UPREGULATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARGININE; BUTYRATES; CELL SURVIVAL; CYCLIC AMP; DIPHTHERIA TOXIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR BETA SUBUNIT; LEUKEMIA; LYMPHOMA; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; RESPONSE ELEMENTS; SECOND MESSENGER SYSTEMS; UP-REGULATION;

EID: 0036889625     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(02)00059-0     Document Type: Article

References (32)

1. Williams D.P., Parker K., Bacha P., Bishai W., Borowski M., Genbauffe F.et al. Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Eng. 1:1987;493-498.
2. Nichols J., Foss F., Kuzel T.M., LeMaistre C.F., Platanias L., Ratain M.J.et al. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Eur. J. Cancer. 33(Suppl 1):1997;S34-36.
3. Re G.G., Waters C., Poisson L., Willingham M.C., Sugamura K., Frankel A.E. Interleukin 2 (IL-2) receptor expression and sensitivity to diphteria fusion toxin DAB389IL-2 in cultured hematopoietic cells. Cancer Res. 56:1996;2590-2595.
4. Papini E., Sandona D., Rappuoli R., Montecucco C. On the membrane translocation of diphtheria toxin: at low pH the toxin induces ion channels on cells. EMBO J. 7:1988;3353-3359.
5. Williams D.P., Snider C.E., Strom T.B., Murphy J.R. Structure/function analysis of interleukin-2-toxin (DAB486-IL-2): fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J. Biol. Chem. 265:1990;11885-11889.
6. Kagan B.L., Finkelstein A., Colombini M. Diphtheria toxin fragment forms large pores in phospholipid bilayer membranes. Proc. Natl. Acad. Sci. U.S.A. 78:1981;4950-4954.
7. Bacha P., Williams D.P., Waters C., Williams J.M., Murphy J.R., Strom T.B. Interleukin 2 receptor-targeted cytotoxicity. interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein. J. Exp. Med. 167:1988;612-622.
8. Waldmann T.A. The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science. 232:1986;727-732.
9. Lin J.X., Leonard W.J. Signaling from the IL-2 receptor to the nucleus. Cytokine Growth Factor Rev. 8:1997;313-332.
10. Foss F.M., Saleh M.N., Krueger J.G., Nichols J.C., Murphy J.R. Diphtheria toxin fusion proteins. Curr. Top. Microbiol. Immunol. 234:1998;63-81.
11. Barnett D., Wilson G.A., Lawrence A.C., Buckley G.A. The interleukin-2 receptor and its expression in the acute leukaemias and lymphoproliferative disorders. Dis. Markers. 6:1988;133-139.
12. Olsen E., Duvic M., Frankel A., Kim Y., Martin A., Vonderheid E.et al. Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol. 19:2001;376-388.
13. Heerdt B.G., Houston M.A., Augenlicht L.H. Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines. Cancer Res. 54:1994;3288-3293.
14. Perrine S.P., Faller D.V. Butyrate-induced reactivation of the fetal globin genes: a molecular treatment for the beta-hemoglobinopathies. Experientia. 49:1993;133-137.
15. Perrine S.P., Ginder G.D., Faller D.V., Dover G.H., Ikuta T., Witkowska H.E.et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. N Engl. J. Med. 328:1993;81-86.
16. Miller A.A., Kurschel E., Osieka R., Schmidt C.G. Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur. J. Cancer Clin. Oncol. 23:1987;1283-1287.
17. Calabresse C., Venturini L., Ronco G., Villa P., Degos L., Belpomme D.et al. Selective induction of apoptosis in myeloid leukemic cell lines by monoacetone glucose-3 butyrate. Biochem. Biophys. Res. Commun. 201:1994;266-283.
18. Urbano A., Koc Y., Foss F.M. Arginine butyrate downregulates p210 bcr-abl expression and induces apoptosis in chronic myelogenous leukemia cells. Leukemia. 12:1998;930-936.
19. Foss FKY, Sanders D, O'Brien M, Faller D, McCaffrey R. Biomodulatory effects of butyric acid derivatives on leukemia and lymphoma cells. Blood 1993;(Suppl 1).
20. Sanders DTS, Faller D, McCaffrey R, Foss F. Phase I clinical trial of arginine butyrate in patients with refractory neoplasms. Proc. ASCO 1995;14.
21. Conley B.A., Egorin M.J., Tait N., Rosen D.M., Sausville E.A., Dover G.et al. Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors. Clin. Cancer Res. 4:1998;629-634.
22. Weidle U.H., Grossmann A. Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment. Anticancer Res. 20:2000;1471-1485.
23. Koyama Y., Adachi M., Sekiya M., Takekawa M., Imai K. Histone deacetylase inhibitors suppress IL-2-mediated gene expression prior to induction of apoptosis. Blood. 96:2000;1490-1495.
24. Witt O., Sand K., Pekrun A. Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways. Blood. 95:2000;2391-2396.
25. Reem G.H., Han X., Marcelli A. Regulation of IL-2β receptor expression and beta-chain mRNA by human thymocytes. Clin. Exp. Immunol. 87:1992;150-156.
26. Pazin M.J., Kadonaga J.T. What' up and down with histone deacetylation and transcription? Cell. 89:1997;325-328.
27. Lin J.X., Leonard W.J. The immediate-early gene product Egr-1 regulates the human interleukin-2 receptor beta-chain promoter through non-canonical Egr and Sp1 binding sites. Mol. Cell Biol. 17:1997;3714-3722.
28. Souleimani A., Asselin C. Regulation of C-fos expression by sodium butyrate in the human colon carcinoma cell line Caco-2. Biochem. Biophys. Res. Commun. 193:1993;330-336.
29. Boffa L.C., Gruss R.J., Allfrey V.G. Manifold effects of sodium butyrate on nuclear function: selective and reversible inhibition of phosphorylation of histones H1 and H2A and impaired methylation of lysine and arginine residues in nuclear protein fractions. J. Biol. Chem. 256:1981;9612-9621.
30. Rivero J.A., Adunyah S.E. Sodium butyrate induces tyrosine phosphorylation and activation of MAP kinase (ERK-1) in human K562 cells. Biochem. Biophys. Res. Commun. 224:1996;796-801.
31. Rolli M., Kotlyarov A., Sakamoto K.M., Gaestel M., Neininger A. Stress-induced stimulation of early growth response gene-1 by p38/stress-activated protein kinase 2 is mediated by a cAMP-responsive promoter element in a MAPKAP kinase 2-independent manner. J. Biol. Chem. 274:1999;19559-19564.
32. Pace B.S., Chen Y.R., Thompson A., Goodman S.R. Butyrate-inducible elements in the human gamma-globin promoter. Exp. Hematol. 28:2000;283-293.